文献速递妇科

左炔诺孕酮释放宫内系统使用与卵巢癌及子宫内膜癌风险降低相关且不增加乳腺癌风险:NOWAC研究结果

Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
PubMed 文献 · Gynecol Oncol · 2018-03-02

基于挪威妇女与癌症研究104,318名女性的前瞻性队列,比较左炔诺孕酮释放宫内系统(LNG-IUS)使用者与从未使用者。中位随访12.5年,使用者卵巢癌多变量RR为0.53(95%CI 0.32,0.88),子宫内膜癌RR为0.22(0.13,0.40),乳腺癌RR为1.03(0.91,1.17)。

要点

  • LNG-IUS使用者卵巢癌风险较从未使用者降低,多变量RR 0.53(95%CI 0.32,0.88)。
  • LNG-IUS使用者子宫内膜癌风险较从未使用者降低,多变量RR 0.22(95%CI 0.13,0.40)。
  • LNG-IUS使用者乳腺癌风险与从未使用者无显著差异,多变量RR 1.03(95%CI 0.91,1.17)。

核心结论

  • 在这项基于人群的前瞻性队列研究中,LNG-IUS使用者较从未使用者卵巢癌和子宫内膜癌风险显著降低,且乳腺癌风险未增加。

研究设计与样本

  • 研究队列来自挪威妇女与癌症研究,共104,318名女性,其中LNG-IUS使用者9,144人,从未使用者95,174人。
  • 暴露信息来自自填问卷,癌症病例通过链接挪威癌症登记处识别。
  • 采用泊松回归估计相对风险(RR)及95%置信区间(CI),使用稳健误差估计。

主要发现

  • 入组中位年龄52岁,平均随访12.5年(标准差3.7),总人年数1,305,435。
  • LNG-IUS使用者中上皮性卵巢癌18例、子宫内膜癌15例、乳腺癌297例。
  • 使用者较从未使用者,卵巢癌多变量RR为0.53(95%CI 0.32,0.88),子宫内膜癌为0.22(0.13,0.40),乳腺癌为1.03(0.91,1.17)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Women with ovarian cancer have poor survival rates, which have proven difficult to improve; therefore primary prevention is important. The levonorgestrel-releasing intrauterine system (LNG-IUS) prevents endometrial cancer, and recent studies suggested that it may also prevent ovarian cancer, but with a concurrent increased risk of breast cancer. We compared adjusted risks of ovarian, endometrial, and breast cancer in ever users and never users of LNG-IUS. METHODS: Our study cohort consisted of 104,318 women from the Norwegian Women and Cancer Study, 9144 of whom were ever users and 95,174 of whom were never users of LNG-IUS. Exposure information was taken from self-administered questionnaires, and cancer cases were identified through linkage to the Cancer Registry of Norway. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated with Poisson regression using robust error estimates. RESULTS: Median age at inclusion was 52years and mean follow-up time was 12.5 (standard deviation 3.7) years, for a total of 1,305,435 person-years. Among ever users of LNG-IUS there were 18 cases of epithelial ovarian cancer, 15 cases of endometrial cancer, and 297 cases of breast cancer. When ever users were compared to never users of LNG-IUS, the multivariable RR of ovarian, endometrial, and breast cancer was 0.53 (95% CI: 0.32, 0.88), 0.22 (0.13, 0.40), and 1.03 (0.91, 1.17), respectively. CONCLUSION: In this population-based prospective cohort study, ever users of LNG-IUS had a strongly reduced risk of ovarian and endometrial cancer compared to never users, with no increased risk of breast cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jareid M, Thalabard JC, Aarflot M, et al. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018. PMID: 29482839. doi:10.1016/j.ygyno.2018.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。